Nanobiotix's IPO Triggers Calls In Europe For More "Citizen Funding"
This article was originally published in The Pink Sheet Daily
Nanotechnology which amplifies the antitumor effects of radiotherapy is being developed by French company Nanobiotix, which has just completed an IPO on NYSE Euronext in Paris, following investment by the general public in France via citizen's funds.
You may also be interested in...
French drug delivery firm Carlina is developing new lipid-based nanoparticle formulations of cancer drugs for pets and patients, and aims to build a proprietary pipeline with the help of collaborations with other companies.
British biotech companies want the U.K. government to adopt a French method of funneling funds into the cash-strapped sector from private individuals in return for favorable rates of investment tax, on grounds that a version of France’s long-running Fonds Commun de Placement dans l'Innovation is needed for small-to-medium-sized biopharma companies in Britain to tap successfully into long-term seed capital.
Peanut Allergy Targeted By DBV Technologies As It Raises $55 Million In Second Euro Biotech IPO This Year
France's DBV Technologies lists on NYSE Euronext in Paris and targets peanut and other food allergies for the first clinical studies of its epicutaneous patches as allergy desensitization therapies.